TWTim Wilhelmi

Tim Wilhelmi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tim Wilhelmi has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does Virtual Reality Enhance Education for Health Professionals in Rheumatology? A Randomized Controlled Pilot Trial (Preprint)

    by Tim Wilhelmi, Fabian Hain, Ann-Christin Hain, Nils Schulz, Axel Hueber, David Simon, Arnd Kleyer, Alexander Pfeil, Ulf Müller-Ladner, Uwe Lange, et al.

    BACKGROUND Non-physician health professionals in rheumatology (HPR) play an increasingly important role in the management of rheumatoid arthritis (RA), yet structured continuing education opportunities remain limited compared with those available to physicians. Virtual reality (VR)-based education has shown superior knowledge outcomes over traditional learning, but no randomized controlled trial has evaluated whether HPR benefit from disease-specific VR-based education, or which format is most effective. OBJECTIVE The aim of this randomized controlled pilot trial was to evaluate whether an immersive VR-enhanced training leads to superior disease-specific knowledge acquisition compared with conventional lecture-based training in HPR, and whether this education yields additional benefits in illness perception and patient-care behavior beyond factual knowledge gains. METHODS This pilot trial randomized HPR (specialized rheumatology assistants and rheumatology nurses) 1:1 at four German rheumatology centers. The intervention group trained with the immersive VR application Rheumality®, delivered via a head-mounted display. The control group received the same content as a conventional PowerPoint lecture. Disease-specific knowledge (Patient Knowledge Questionnaire, PKQ) was assessed at baseline, immediately after training, and at four-week follow-up. The primary outcome was whether knowledge changed differently over time between the two groups. Secondary, exploratory outcomes were illness perception (Brief Illness Perception Questionnaire, BIPQ) and empathy (Consultation and Relational Empathy Measure, CARE). User acceptance and tolerability of VR were assessed descriptively in the intervention group. Group differences over time were analyzed with linear mixed-effects models, using Tukey-adjusted post-hoc comparisons and estimated marginal means (95% CI). RESULTS Of 44 HPR screened, 40 were randomized (VR group: n=20; control group: n=20). Three participants allocated to the VR group did not receive the intervention. Nine participants in the conventional education group were lost to follow-up four weeks after intervention. Linear mixed-effects modeling demonstrated a significant visit-by-group interaction for disease-specific knowledge (χ²=16.54, p < 0.001), indicating different knowledge trajectories between groups. In the VR group, PKQ scores increased from 19.8±2.4 at baseline to 23.1±2.5 immediately after the intervention (p = 0.008) and to 27.8±5.3 after four weeks (p < 0.001), whereas the conventional education group showed no significant improvement over time. No significant group-specific changes were observed for illness perception (BIPQ) or empathy (CARE). User acceptance was high. All participants of the VR group reported a positive overall experience and would recommend the VR application. Adverse events were rare (n=3), mild, and transient (e.g., nausea or dizziness). CONCLUSIONS This pilot trial provides evidence that immersive VR-enhanced training was associated with greater and sustained disease-specific knowledge gains in HPR compared with conventional lecture-based training, with the effect widening over the four-week follow up. The VR application demonstrated high user acceptance and good tolerability. CLINICALTRIAL DRKS00021507

  • Open Access

    Effect of pre-visit computer-assisted history-taking with a structured copy-ready summary on documentation completeness in screening for inflammatory rheumatic diseases: a randomized pilot study

    by Anna Roemer, Tim Wilhelmi, Daniel Fink, Manuel Göbel, Juliana Hack, Jonathan Bamberger, Felix Mühlensiepen, Karolina Gente, Sebastian Kuhn, Philipp Klemm, et al.

    Background: Clinical encounters in outpatient care are constrained by high demand, limited consultation time, and documentation requirements. Computer-assisted history-taking (CAHT) may improve the structured collection of patient information before consultations and disease screening, but evidence is limited. This randomized pilot study evaluated whether pre-visit CAHT combined with a copy-ready summary increased documentation completeness and assessed patient and physician acceptance. Methods: MAESTRI was a multicenter, parallel-group, randomized pilot study conducted across rheumatology, dermatology, and orthopedics outpatient services. Adults at increased risk of an underlying inflammatory rheumatic disease (IRD) were randomized to pre-visit CAHT or usual care. Specialty-specific questionnaires generated structured narrative summaries covering predefined screening-relevant items. The primary outcome was documentation completeness, assessed by a blinded reviewer as the percentage of these predefined items present in the final clinical documentation. Secondary and exploratory outcomes included patient and physician acceptance, usability ratings, and free-text feedback. Results: Of 45 screened patients, 43 were randomized and analyzed. The mean age was 54.2 years (SD 14.3), and 29 participants (67.4%) were female. All intervention-group clinical notes contained the generated summary. Overall median documentation completeness was 100.0% (IQR 100.0-100.0) in the intervention group compared with 46.9% (IQR 10.0-68.8) in the control group ( p < 0.001), with consistent differences across rheumatology, dermatology, and orthopedics. CAHT acceptance was high among both patients and physicians, with 41 of 43 patients (95.3%) willing to complete and the six responding physicians (100%) willing to offer digital pre-visit questionnaires before future appointments. Qualitative feedback was predominantly positive, with patients reporting that pre-visit questionnaires could improve consultation preparation, support recall of symptoms, and help physicians focus the visit on relevant issues. Some participants emphasized that digital questionnaires should complement, rather than replace, direct physician interaction. Conclusions: Pre-visit CAHT combined with a structured, copy-ready summary substantially increased the completeness with which predefined screening-relevant information was transferred into clinical documentation while also suggesting high acceptance among both patients and physicians. These findings support further evaluation in a larger trial assessing workflow impact and clinical impact. Trial registration: The study was registered at German Clinical Trials Register (DRKS; ID: DRKS00036519). Date of Registration: 2025-03-31.

  • Open Access

    Development and Nationwide Multicentre Evaluation of Guideline-Grounded Large Language Model Chatbots to Support Patient Self-Management and Education in Rheumatology

    by Tim Wilhelmi, Vanessa Bartsch, Marius Platt, Asarnusch Rashid, Johannes Hornig, Martin Krusche, Axel J Hueber, Daniel Fink, Alexander Pfeil, Gabriel Dischereit, et al.

    Patients with rheumatic diseases have persistent information needs that are not fully addressed in routine care. We developed and evaluated guideline-grounded, large language model (LLM) chatbots to support patient self-management and education in rheumatology. Ten disease-specific chatbots based on German guidelines were co-developed and deployed through 13 rheumatology centres and six patient organisations. Chatbot users rated responses and completed a questionnaire. User questions, feedback, and response characteristics were analysed using category-based coding and a six-dimensional LLM-as-a-judge assessment, with LLM-based ratings compared with rheumatologist ratings in random subsets. Between September 2025 and January 2026, 6291 questions were recorded. Thirteen question categories were identified, most commonly disease-specific questions (50.2%), medication and monitoring (37.3%) and diagnostics (28.2%). The chatbots were unable to answer in 263 interactions (4.2%). Of 2671 responses rated by users, 2481 (92.9%) received a positive rating. Insufficient detail was the most common reason for negative ratings (125/190, 65.8%). Among 602 questionnaire respondents, 84.6% reported that the chatbot was easy to use, 84.1% that answers were easy to understand, and 80.2% that it was a useful addition to patient education. In the LLM-based evaluation, 95.3% of answers were rated as completely safe and 79.1% as completely correct. Guideline adherence was assessed separately, with 45.0% rated as fully adherent; agreement with physician assessment was weak. Guideline-grounded chatbots received predominantly positive user feedback in real-world use, while LLM-based evaluation suggested that most responses were safe and correct. User questions and feedback may help guide iterative improvements to source content and patient education materials. Further studies are needed to evaluate educational effectiveness and independently validate response quality and clinical safety.


  • Open Access

    A hip that breaks the scale

    by Nils Schulz, Tim Wilhelmi, Pascal van Wijnen, Ulf Müller-Ladner, Philipp Klemm

  • Open Access

    Effects of locally applied water-filtered infrared a irradiation adjunctive to iloprost and carbon dioxide hand baths in patients with systemic sclerosis and severe Raynaud’s phenomenon – a randomized controlled trial

    by Nils Schulz, Priyanka Boettger, Joachim Bär, Tim Wilhelmi, Pascal van Wijnen, Ulf Müller-Ladner, Uwe Lange, Philipp Klemm

    Up to 95% of patients with systemic sclerosis (SSc) experience Raynaud’s phenomenon (RP), characterized by recurrent digital vasospasm triggered by cold or stress, leading to ischemia, pain, and, i...


  • Open Access

    Correction to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study

    by Nils Schulz, Thomas Asendorf, Pascal van Wijnen, Tim Wilhelmi, Ulf Müller-Ladner, Uwe Lange, Philipp Klemm

  • Open Access

    Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study

    by Nils Schulz, Thomas Asendorf, Pascal van Wijnen, Tim Wilhelmi, Ulf Müller-Ladner, Uwe Lange, Philipp Klemm

    Rheumatoid arthritis (RA) is associated with systemic bone loss and thus an established risk factor for osteoporosis. Janus kinase inhibitors (JAKi) have shown osteo-protective effects. However, clinical data on the effects of baricitinib on bone mineral density (BMD) remain limited. Therefore, we investigated the effects of a 1-year treatment with baricitinib on BMD in RA patients. Patients with active RA beginning treatment with baricitinib were included. BMD was measured at the lumbar spine and femoral neck using Dual-Energy X-Ray Absorptiometry (DXA). Disease activity was assessed using DAS28-CRP and cDAI. The primary endpoint was the change in BMD after 12 months. Secondary endpoints evaluated changes in disease activity, prednisolone dose and alkaline phosphatase (AP) levels and its relation to BMD. A total of 46 RA patients were recruited, of whom 26 completed the study. Overall, BMD remained stable. Non-responders to baricitinib (based on DAS28-CRP) showed a significant decline in spine BMD (− 2.12%, p = 0.039), while responders showed stable BMD. The between-group difference in spine BMD ( p = 0.008) and T-score ( p = 0.012) was significant. Demographic and clinical characteristics did not differ significantly between groups. Disease activity (DAS28-CRP: p = 0.003; cDAI: p = 0.007), prednisolone dose ( p = 0.006), and AP levels ( p = 0.03) all improved significantly. Under baricitinib, BMD loss appeared stabilized in RA patients. Non-responders to baricitinib experienced a significant loss of BMD with a significant difference to responders raising the question if seen effects are achieved by controlling disease activity or if there is an additional explicit JAKi effect on bone metabolism. Trial registration number: DRKS00020780, date: 13.3.2020.


  • Open Access

    Effectiveness and safety of antiresorptive drugs in patients with systemic sclerosis—a retrospective monocentric study

    by Nils Schulz, Jonas Neumann, Tim Wilhelmi, Pascal van Wijnen, Ulf Müller-Ladner, Philipp Klemm